Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Harvard Bioscience Inc.

    NASDAQ: HBIO · Real-Time Price · USD
    0.51
    0.00 (0.24%)
    At close: Jun 16, 2025, 3:59 PM
    0.51
    -1.05%
    Pre-market: Jun 17, 2025, 09:01 AM EDT

    Harvard Bioscience Statistics

    Share Statistics

    Harvard Bioscience has 44.21M shares outstanding. The number of shares has increased by 1.48% in one year.

    Shares Outstanding

    n/a
    		 44.21M

    Shares Change (YoY)

    n/a
    		 1.48%

    Shares Change (QoQ)

    n/a
    		 1.05%

    Owned by Institutions (%)

    n/a
    		 71.18%

    Shares Floating

    n/a
    		 37.41M

    Failed to Deliver (FTD) Shares

    n/a
    		 3,100

    FTD / Avg. Volume

    n/a
    		 0.03%

    Short Selling Information

    The latest short interest is 6.64M, so 15.03% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 6.64M

    Short % of Shares Out

    n/a
    		 15.03%

    Short % of Float

    n/a
    		 16.25%

    Short Ratio (days to cover)

    n/a
    		 1

    Valuation Ratios

    The PE ratio is -7.41 and the forward PE ratio is 8.48. Harvard Bioscience's PEG ratio is -0.03.

    PE Ratio

    n/a
    		 -7.41

    Forward PE

    n/a
    		 8.48

    PS Ratio

    n/a
    		 0.98

    Forward PS

    n/a
    		 0.2

    PB Ratio

    n/a
    		 1.45

    P/FCF Ratio

    n/a
    		 -76.3

    PEG Ratio

    n/a
    		 -0.03
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Harvard Bioscience.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 0.82, with a Debt / Equity ratio of 0.7.

    Current Ratio

    n/a
    		 0.82

    Quick Ratio

    n/a
    		 0.4

    Debt / Equity

    n/a
    		 0.7

    Debt / EBITDA

    n/a
    		 -30.19

    Debt / FCF

    n/a
    		 -36.96

    Interest Coverage

    n/a
    		 -1.94

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $285,257.58

    Profits Per Employee

    n/a
    		 $-37,590.91

    Employee Count

    n/a
    		 330

    Asset Turnover

    n/a
    		 0.74

    Inventory Turnover

    n/a
    		 1.69

    Taxes

    Income Tax

    n/a
    		 740K

    Effective Tax Rate

    n/a
    		 -6.34%

    Stock Price Statistics

    The stock price has increased by -82.53% in the last 52 weeks. The beta is 1.55, so Harvard Bioscience's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.55

    52-Week Price Change

    n/a
    		 -82.53%

    50-Day Moving Average

    n/a
    		 0.4

    200-Day Moving Average

    n/a
    		 1.55

    Relative Strength Index (RSI)

    n/a
    		 55.03

    Average Volume (20 Days)

    n/a
    		 11,701,525

    Income Statement

    In the last 12 months, Harvard Bioscience had revenue of 94.14M and earned -12.4M in profits. Earnings per share was -0.28.

    Revenue

    n/a
    		 94.14M

    Gross Profit

    n/a
    		 54.77M

    Operating Income

    n/a
    		 -6.21M

    Net Income

    n/a
    		 -12.4M

    EBITDA

    n/a
    		 -1.47M

    EBIT

    n/a
    		 -8.46M

    Earnings Per Share (EPS)

    n/a
    		 -0.28
    Full Income Statement

    Balance Sheet

    The company has 4.11M in cash and 44.49M in debt, giving a net cash position of -40.39M.

    Cash & Cash Equivalents

    n/a
    		 4.11M

    Total Debt

    n/a
    		 44.49M

    Net Cash

    n/a
    		 -40.39M

    Retained Earnings

    n/a
    		 -158.01M

    Total Assets

    n/a
    		 79.8M

    Working Capital

    n/a
    		 -10.7M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was 1.44M and capital expenditures -2.64M, giving a free cash flow of -1.2M.

    Operating Cash Flow

    n/a
    		 1.44M

    Capital Expenditures

    n/a
    		 -2.64M

    Free Cash Flow

    n/a
    		 -1.2M

    FCF Per Share

    n/a
    		 -0.03
    Full Cash Flow Statement

    Margins

    Gross margin is 58.18%, with operating and profit margins of -6.6% and -13.18%.

    Gross Margin

    n/a
    		 58.18%

    Operating Margin

    n/a
    		 -6.6%

    Pretax Margin

    n/a
    		 -12.39%

    Profit Margin

    n/a
    		 -13.18%

    EBITDA Margin

    n/a
    		 -1.57%

    EBIT Margin

    n/a
    		 -6.6%

    FCF Margin

    n/a
    		 -1.28%

    Dividends & Yields

    HBIO does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for HBIO is $3, which is 488.2% higher than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $3

    Price Target Difference

    n/a
    		 488.2%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 2
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Nov 4, 2013. It was a forward split with a ratio of 1319:1000.

    Last Split Date

    n/a
    		 Nov 4, 2013

    Split Type

    n/a
    		 forward

    Split Ratio

    n/a
    		 1319:1000

    Scores

    Altman Z-Score

    n/a
    		 -4.41

    Piotroski F-Score

    n/a
    		 5

    Add to Watchlist